Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$530M |
| 2 |
AbbVie
ABBV
|
+$429M |
| 3 |
Boston Scientific
BSX
|
+$292M |
| 4 |
Snap
SNAP
|
+$241M |
| 5 |
Royalty Pharma
RPRX
|
+$223M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$327M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$295M |
| 3 |
AMTD
TD Ameritrade Holding Corp
AMTD
|
+$294M |
| 4 |
Sysco
SYY
|
+$209M |
| 5 |
Shopify
SHOP
|
+$176M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.65% |
| 2 | Healthcare | 19.7% |
| 3 | Consumer Discretionary | 10.81% |
| 4 | Financials | 9.9% |
| 5 | Communication Services | 8.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CYBR
1076
DELISTED
CyberArk
CYBR
| $1.4M | ﹤0.01% |
14,067
-2,518
| -15% | -$245K |
|
1077
Globant
GLOB
$1.67B
| $1.39M | ﹤0.01% |
9,247
-1,631
| -15% | -$201K |
|
1078
Universal Health Services
UHS
$10.3B
| $1.38M | ﹤0.01% |
14,826
-470,043
| -97% | -$47M |
|
1079
Jabil
JBL
$30.6B
| $1.37M | ﹤0.01% |
42,680
-71,351
| -63% | -$2.05M |
|
1080
Zai Lab
ZLAB
$2.08B
| $1.37M | ﹤0.01% |
+16,667
| New | +$1.13M |
|
1081
Coherent
COHR
$44.9B
| $1.36M | ﹤0.01% |
28,903
-10,957
| -27% | -$434K |
|
1082
Gaming and Leisure Properties
GLPI
$13B
| $1.35M | ﹤0.01% |
39,160
-62,306
| -61% | -$1.94M |
|
|
PS
1083
DELISTED
Pluralsight, Inc. Class A Common Stock
PS
| $1.35M | ﹤0.01% |
+75,000
| New | +$1.27M |
|
|
GBIO
1084
DELISTED
Generation Bio
GBIO
| $1.35M | ﹤0.01% |
+6,417
| New | +$1.43M |
|
1085
Medifast
MED
$108M
| $1.35M | ﹤0.01% |
9,711
+1,780
| +22% | +$163K |
|
|
MRSN
1086
DELISTED
Mersana Therapeutics
MRSN
| $1.34M | ﹤0.01% |
+2,295
| New | +$784K |
|
1087
Parsons
PSN
$4.19B
| $1.34M | ﹤0.01% |
+36,963
| New | +$1.39M |
|
1088
Zions Bancorporation
ZION
$10.2B
| $1.33M | ﹤0.01% |
39,027
-33,225
| -46% | -$1.05M |
|
1089
Albemarle
ALB
$13.5B
| $1.29M | ﹤0.01% |
16,724
+806
| +5% | +$54.8K |
|
|
EFOR
1090
Everforth Inc
EFOR
$969M
| $1.29M | ﹤0.01% |
19,318
+11,269
| +140% | +$598K |
|
1091
Qualys
QLYS
$4.81B
| $1.27M | ﹤0.01% |
12,262
-9,312
| -43% | -$976K |
|
|
ARNA
1092
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.27M | ﹤0.01% |
20,115
-2,434
| -11% | -$134K |
|
1093
Lennox International
LII
$15.1B
| $1.26M | ﹤0.01% |
5,420
-882
| -14% | -$178K |
|
1094
Sutro Biopharma
STRO
$390M
| $1.26M | ﹤0.01% |
16,311
-514
| -3% | -$49.3K |
|
|
CMA
1095
DELISTED
Comerica
CMA
| $1.26M | ﹤0.01% |
33,031
-6,327
| -16% | -$221K |
|
1096
CNA Financial
CNA
$14.9B
| $1.24M | ﹤0.01% |
38,575
-2,978
| -7% | -$91.7K |
|
1097
The Mosaic Company
MOS
$7.26B
| $1.21M | ﹤0.01% |
96,385
-357,736
| -79% | -$4.29M |
|
1098
Cenovus Energy
CVE
$54.1B
| $1.19M | ﹤0.01% |
255,225
+4,041
| +2% | +$15.5K |
|
1099
Trex
TREX
$4.46B
| $1.18M | ﹤0.01% |
18,108
+124
| +0.7% | +$6.61K |
|
|
ONC
1100
BeOne Medicines Ltd
ONC
$34.2B
| $1.16M | ﹤0.01% |
6,168
-596
| -9% | -$97K |
|
Similar funds
Janus Henderson Group's Q2 2020 Portfolio in Review
As of Q2 2020, Janus Henderson Group held 1,423 positions worth $178B, up 23% from $145B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Janus Henderson Group's Q2 2020 filing shows 132 new, 511 increased, 643 reduced and 125 closed positions. Its largest new stake was Royalty Pharma: 4,507,138 shares worth $219M. The largest sale was Boeing, an estimated $327M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q2 2020 buy was Royalty Pharma: 4,507,138 shares worth $219M.
- Janus Henderson Group added most to T-Mobile US in Q2 2020, an estimated $530M increase.
- Janus Henderson Group's biggest Q2 2020 reduction was Boeing, cutting an estimated $327M.
- Janus Henderson Group fully exited Allergan plc in Q2 2020, selling an estimated $128M.
- Janus Henderson Group's ten largest holdings make up 23% of its $178B portfolio in Q2 2020.
- Janus Henderson Group opened 132 new positions and closed 125 in Q2 2020.
- Janus Henderson Group's portfolio value rose 23% quarter-over-quarter to $178B.
Based on Janus Henderson Group's 13F filing for Q2 2020, filed 14 Aug 2020.